AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05081102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of oxycodone 5 mg/ibuprofen 400 mg
Description: receive one (1) experimental drug tablet (FCD of oxycodone 5mg/ibuprofen 400mg) + one (1) Tylex® placebo.
Study NCT05081102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylex
Description: receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
Study NCT04863209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper cervical manipulation
Description: The patient will receive an upper cervical manipulation as described in the Experimental Group 1.
Study NCT04863209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion manipulation
Description: The patient will receive a sphenopalatine ganglion as described in the Experimental Group 2.
Study NCT05828511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab will be administered by intravenous (IV) infusion
Study NCT06432868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Solarplast (R)
Description: Daily supplementation for 28 days prior to heavy resistance exercise.
Study NCT06432868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily supplementation for 28 days prior to heavy resistance exercise.
Study NCT04869020 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Otoband
Description: Participants with vertigo will wear the Otoband set at their chosen power level when experiencing symptoms.
Study NCT04869020 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sham A
Description: Sham Device A is an OtoBand in which the transducer is modified so that the vibrations are not targeted at the vestibular system.
Study NCT04869020 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sham B
Description: Sham Device B is an OtoBand that operates at power settings found to be nontherapeutic against vertigo associated with virtual reality.
Study NCT06469359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saliva sampling
Description: Saliva is collected using Oracol (Malvern Medical Developments)
Study NCT04479527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab for injection is used to treat patients with relapsed or refractory classic Hodgkin lymphoma who have undergone at least second-line chemotherapy. Approved by the Drug Administration (NMPA) on March 4, 2020, for the treatment of patients with advanced hepatocellular carcinoma who have previously received sorafenib therapy and/or oxaliplatin-containing chemotherapy.Apatinib Mesylas is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR to play an anti-angiogenic effect. It has been approved by the China Food and Drug Administration (CFDA) in November 2014. It is used as a monotherapy for advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma that has progressed or relapsed after receiving two kinds of systemic chemotherapy. Apatinib Mesylas can effectively inhibit VEGFR2 at very low concentrations, and higher concentrations can also inhibit PDGFR, c-Kit and c-Src and other kinases.
Study NCT05866263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: green walking and intelligence gam
Description: The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.
Study NCT05866263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: green walking and intelligence gam
Description: The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.
Study NCT05575427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: The patients will receive minocycline oral between 7-28 days
Study NCT05575427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin or Cotrimoxazole
Description: The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days
Study NCT05575427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin or Cotrimoxazole
Description: The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days
Study NCT05575427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule without active compound
Study NCT04865458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC89736
Description: HEC89736 tablets QD every 28 days for each cycle
Study NCT01341548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide nasal solution 0.01%
Description: 20ug/dose, BID for 7 days 0.1 ml to each nostril
Study NCT01341548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Civamide nasal solution 0.01%
Description: 20ug/dose, BID for 7 days 0.1 ml to each nostril
Study NCT06500728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescein and Indocyanine green Angiography
Description: The ophthalmologist frequently recommends fluorescein (FAG) and indocyanine green angiography (ICGA) at baseline (T0) to evaluate retinal and choroidal vascularisation. They can be repeated also after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4) or 26 ± 2 weeks (T5).
Study NCT06500728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution Optical Coherence Tomography
Description: The ophthalmologist often suggests performing HR-OCT initially (T0) to assess the width of the macula and optic nerve with potential signs of ischemic lesions in these areas. This assessment can also be repeated after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
Study NCT06500728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Angio-Optical Coherence Tomography
Description: The ophthalmologist often suggests OCT-A at the beginning (T0) to assess the retinal and choroidal vascularization. These tests can also be done after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
Study NCT06277830 — intervention group
Intervention type: DEVICE
Intervention: Wearable sensor
Description: Participants will wear a pendant sensor for 7 days and then participate in an on-site examination with using a tablet designed to evaluate weakness in MG.
Study NCT05963919 — intervention group
Intervention type: OTHER
Intervention: 6-minute walk test
Description: Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
Study NCT05963919 — intervention group
Intervention type: OTHER
Intervention: Pulmonary function test
Description: Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) by ATS/ERS criteria. Forced expiratory volume in 1 second (FEV1) and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values.
Study NCT05963919 — intervention group
Intervention type: OTHER
Intervention: Respiratory muscle strength test
Description: Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
Study NCT05963919 — intervention group
Intervention type: OTHER
Intervention: Lower extremity muscle strength test
Description: The 30-Second Chair Test is administered using a folding chair without arms, with a seat height of 17 inches (43.2 cm). The chair, with rubber tips on the legs, is placed against a wall to prevent it from moving. The participant is seated in the middle of the chair, back straight; feet approximately a shoulder width apart, and placed on the floor at an angle slightly back from the knees, with one foot slightly in front of the other to help maintain balance. Arms are crossed at the wrists and held against the chest. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand.
Study NCT05409651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study.
Study NCT06258746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]HSK31679
Description: A single oral dose of 160 mg/100 μCi \[14C\]HSK31679 after fasting for at least 10 hours.
Study NCT06469359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Isolation of peripheral blood mononuclear cells (PBMC) and serum from blood
Study NCT06469359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA
Description: ELISA to measure antibody responses in mucosal fluids and blood
Study NCT06469359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neutralization test
Description: Neutralization test to measure neutralizing antibody responses in mucosal fluids and blood to measure neutralizing antibody responses in mucosal fluids and blood
Study NCT06281873 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closure by PRF membrane
Description: Oral fistulectomy was done with proper curettage. EMMA was performed. closure of the OAF by application of PRF membrane and covering it with an acrylic splint
Study NCT06211270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRESH
Description: FRESH-T2D Intervention consisting of bimonthly food, recipes, and diabetes self-management resources + 4 meetings with Registered Dietitian Nutritionists x 6 months duration
Study NCT06211270 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FRESH
Description: FRESH-T2D Intervention consisting of bimonthly food, recipes, and diabetes self-management resources + 4 meetings with Registered Dietitian Nutritionists x 6 months duration
Study NCT05380999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Methylation tests of nucleic acids extracted from mature red blood cells (RBCs)
Description: Up to 15 ml of peripheral blood will be collected from each subject, and the blood specimen will be processed to isolate mature red blood cells and extract the DNA and RNA from RBCs. DNA and RNA methylation will be tested by next-generation sequencing (NGS).
Study NCT04687618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula withAutomatic control of FiO2 using OAM
Description: The target oxygen saturation (SpO2) value will to be determined and set by the clinician according to specific patient needs. The target SpO2 in preterm infants is 90-95% with alarm limits at 89-96%. In automatic control of oxygen, the OAM automatically increases or decreases the FiO2 (oxygen delivery) setting on the Vapotherm Precision Flow based on pulse oximetry readings of the OAM. The target saturation will be set at 93% and the FiO2 will be adjusted by OAM to maintain the target saturation. The automated FiO2 setting can be overridden for a clinician pre-set period of time (30-120 sec) by simply manually adjusting the FiO2 on the Precision Flow. Automated control resumes after the clinicians pre-set period of time (30-120 sec) based on the current SpO2 and FiO2. The OAM utilizes a feedback control algorithm that receives a patient's oxygen saturation value from a build in pulse oximetry device (Masimo SET OEM - normal sensitivity, averaging time window set at 8 seconds).
Study NCT04687618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula with manual control of FiO2
Description: In manual control of oxygen all FiO2 adjustments will be done by the clinical staff to maintain saturations between 90-95%. The alarm limits will be 89-96%.
Study NCT06469359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISPot
Description: ELISPot to measure cellular responses in blood
Study NCT05113602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URGOnight
Description: EEG dry electrodes portable device
Study NCT05113602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enobio
Description: EEG wet electrodes portable device
Study NCT05416632 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Athrometer
Description: Arthrometer
Study NCT05316051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inverted foot orthoses
Description: Inverted functional orthoses will be used in this study based on Blake (1986) inverted orthotic technique. Two groups of foot orthosis will be fabricated with two different inverted angles: 25° inverted angle and 15° inverted angle.
Study NCT05628415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-powered AeonTM Endostapler (according to manufacturer medical device classification IIb)
Description: Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the non-powered Aeon™ Endostapler (Lexington medical) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
Study NCT05628415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echelon FLEX™ Powered plus Stapler (according to manufacturer medical device classification IIb)
Description: Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the Echelon FLEX™ Powered plus Stapler (Ethicon) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
Study NCT06433544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-week online mindfulness course
Description: The experimental group received a 6-week online mindfulness course, once a week for 90 minutes each session.
Study NCT06092580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AWT020
Description: Participants receiving AWT020 once every two weeks at designated dose levels
Study NCT06469359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcriptomics
Description: Transcriptomics to quantify the gene expression of immunological markers in blood
Study NCT06275490 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Partially Demineralized Dentin Block
Description: The extracted tooth will undergo grinding using the tooth transformer device. The produced dentin graft will be of a particle size 400-800 μm. Afterwards.~-Prepare the partially demineralized dentin block, the L-PRF membranes will be cut into small pieces and mixed with the dentin particles at a ratio of 2 membranes to 0.5 g of dentin, providing a 1:1 volume ratio. The liquid fibrinogen will be added to the homogeneous mixture, and while shaping the mixture into the desired form it will be gently stirred for approximately 10 seconds. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming a sturdy block known as the dentin block, which serves as a convenient and compact graft .The extracted socket will be filled with partially demineralized autogenous dentin graft.
Study NCT06275490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Partially Demineralized Dentin Block
Description: The extracted tooth will undergo grinding using the tooth transformer device. The produced dentin graft will be of a particle size 400-800 μm. Afterwards.~-Prepare the partially demineralized dentin block, the L-PRF membranes will be cut into small pieces and mixed with the dentin particles at a ratio of 2 membranes to 0.5 g of dentin, providing a 1:1 volume ratio. The liquid fibrinogen will be added to the homogeneous mixture, and while shaping the mixture into the desired form it will be gently stirred for approximately 10 seconds. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming a sturdy block known as the dentin block, which serves as a convenient and compact graft .The extracted socket will be filled with partially demineralized autogenous dentin graft.
Study NCT06275490 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF block
Description: The same procedure will be performed for preparing the L-PRF block by mixing the L-PRF membranes with xenograft. In both groups, the placed graft will be covered with a L-PRF membrane .The L-PRF clots obtained after 12 min of centrifugation will be placed in the Xpression box (IntraSpin, Intra-Lock, Florida, USA) for 5 min to gently compress (by gravity) into membranes.
Study NCT06275490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-PRF block
Description: The same procedure will be performed for preparing the L-PRF block by mixing the L-PRF membranes with xenograft. In both groups, the placed graft will be covered with a L-PRF membrane .The L-PRF clots obtained after 12 min of centrifugation will be placed in the Xpression box (IntraSpin, Intra-Lock, Florida, USA) for 5 min to gently compress (by gravity) into membranes.
Study NCT04841200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese medicine compound combined with symptomatic treatments
Description: All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd.~Each type of granule will be given orally, twice a day, for 52 weeks.
Study NCT04841200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese medicine compound placebo combined with symptomatic treatments
Description: All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 placebo Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules placebo for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules placebo for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules placebo for syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. The appearance, shape, color and packaging of Chinese medicine compound placebo are the same as those of drugs.~Each type of granule will be given orally, twice a day, for 52 weeks.
Study NCT06578728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 25mg/mL intralesional injection into nail bed/nail matrix
Study NCT06578728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 10mg/mL
Description: 10mg/mL intralesional injection into nail bed/nail matrix
Study NCT06578728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: saline intralesional injection into nail bed/nail matrix
Study NCT04784780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10mg
Description: Patients with chronic constipation are administered Elobixibat 10mg for 12 weeks
Study NCT04784780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with chronic constipation are administered placebo for 12 weeks
Study NCT05129020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sparrow Fledging Therapy System
Description: tAN sessions will be administered up to four times per day for up to 20 days total. Active tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
Study NCT05980767 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary Peripheral Nerve Stimulation System
Description: Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation.
Study NCT05129020 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Sparrow Fledging Therapy System
Description: Participants randomized to the sham group will have the device earpiece applied at the same timepoints and for the same duration as the active group, but stimulation will not be turned on. tAN sessions will be administered up to four times per day for up to 20 days total. Sham tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
Study NCT06649201 — intervention group
Intervention type: OTHER
Intervention: Vulvovaginal Symptom Questionnaire
Description: Participants will undergo assessment of vulvovaginal symptoms via the vulvovaginal questionnaire once pre-transplant, six months, and develop months post-transplant.